StemCells drops Batten, failing to find any patients
This article was originally published in Scrip
Executive Summary
Cell therapy specialist, StemCells Inc. is shelving a Phase Ib clinical trial in children with the rare genetic neurogenerative disorder neuronal ceroid lipofuscinosis (NCL), also known as Batten disease, having failed to identify any patients who fit the entry criteria. The trial design, which aimed to show that StemCells' purified human neural stem cells (HuCNS-SC) could be neuroprotective, called for pre-symptomatic patients, at a very early stage of the disease. However, early diagnosis is difficult, leaving the Palo Alto, California company wondering how to test the efficacy of its approach. The market wondered, too, with the company's shares down 8.7% on the news, closing at $0.79.
You may also be interested in...
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio raises $16.9M as it advances PhIII premature ejaculation drug
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Money talks: Verastem leverages IPO to build cancer stem cell pipeline
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.